Sickle Cell Disease

Pivotal Phase III FLOCOR Trial for Disease Treatment Begins

Published in Blood Weekly, March 30th, 1998

CytRx Corp., Atlanta, Georgia, announced the enrollment of the first patient in the Phase III trial investigating FLOCOR for the treatment of the painful vascular occlusive crisis of sickle cell disease.

The Phase III trial is one of the largest sickle cell trials ever conducted with a target of 350 patients in 30 sites throughout the United States. Dr. J. Michael Grindel, CytRx, added, "This study has been powered statistically to confirm what we have already seen in previous tests conducted by ourselves and others. Based on our discussions with the FDA on the endpoints in the study protocol, we believe that if we can show a statistically significant improvement over...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1998-03-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry